INTRODUCTION AND OBJECTIVES:
There is a growing body of evidence suggesting possible therapeutic role of statin medications on advanced prostate cancer outcomes. However, little is known regarding the impact of the type of statin medications used, the dose of statins received, or the duration of treatment with this class of medications on PCa outcomes. Our goal was to investigate the impact of the statin type, dose and duration on oncologic outcomes in patients with advanced prostate cancer who are treated with androgen deprivation therapy (ADT).
METHODS: We used the national VA database to identify all men diagnosed with PCa who are receiving ADT and were treated with statin medications for at least 6 months after PCa diagnosis between 2000 and 2008 with follow-up through May 2016. Patients were then stratified based on the type of statins (hydrophilic vs. lipophilic), the cumulative dose of statins (based on WHO defined daily dose for each statin medication), and the total duration of statins use (< 12 months, 12-24 months, 24-36 months, and ! 36 months). Multivariable Cox proportional hazards analyses were performed to assess the association between cumulative duration, dose, and type of statin used and prostate cancer specific survival (PCSS), overall survival (OS) and skeletal related events (SREs).
RESULTS: A total of 53,582 PCa patients on ADT were included in the study cohort. The median patient age was 74 years and majority (65.7%) were Caucasian. Seventy-five percent of patients had Charlson co-morbidity index of 1. The median PSA at time of diagnosis was 9.6 ng/dl. On multivariable Cox proportional hazards analysis controlling for multiple baseline characteristics, increased duration > 36 months (HR 0.48 , a large real-world study of sipuleucel-T in men with mCRPC, offers an opportunity to examine patients who experienced longer term (!3 yr) survivals after receiving sipuleucel-T. The current analysis seeks insights regarding these patients, especially noting the timing of sipuleucel-T relative to the other FDA-approved treatments in the modern era.
METHODS: Men with mCRPC receiving sipuleucel-T, given every 2 weeks x 3, were eligible for PROCEED. Follow-up continued until death, study withdrawal, or a minimum of 3 years. Long-term survivors were defined as those who survived !3 yr. Baseline characteristics and treatments received pre/post-sipuleucel-T are reported in this ad-hoc subgroup analysis. RESULTS: From 2011 -2014 , 1902 men received !1 sipuleucel-T infusion. Of these, an estimated 42.3% survived !3yr. At baseline, long-term survivors (OS !3 yr) and those who survived <3 yr had no notable differences in laboratory measures or patterns of metastatic spread. Long-term survivors were less likely to have received OS-prolonging therapies (abiraterone, enzalutamide, docetaxel, or cabazitaxel) prior to sipuleucel-T, but received more lines of OS-prolonging therapies after sipuleucel-T, compared to those who survived < 3yr (median 2.0 v. 1.0).
CONCLUSIONS: In the modern era, a considerable number of patients with mCRPC survived !3 yr. These patients were more likely to have received sipuleucel-T as 1st-line therapy for mCRPC than those with survivals <3 yr. Long-term survivors also received more lines of agents known to improve OS in mCRPC after sipuleucel-T.
